FDA approves Alzheimer’s drug lecanemab amid safety concerns

Protein clumps called amyloid plaques (gold, among blue neurons in this computer illustration) are a hallmark of Alzheimer’s disease.Credit: Juan Gaertner/SPL The US Food and Drug Administration (FDA) has approved lecanemab, the second-ever treatment for Alzheimer’s disease that is intended to tackle the root of the condition and the slow cognitive decline that results. Researchers […]